| __timestamp | Ligand Pharmaceuticals Incorporated | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 12122000 | 19586000 |
| Thursday, January 1, 2015 | 13380000 | 29135000 |
| Friday, January 1, 2016 | 21221000 | 42791000 |
| Sunday, January 1, 2017 | 26887000 | 49577000 |
| Monday, January 1, 2018 | 27863000 | 89209000 |
| Tuesday, January 1, 2019 | 55908000 | 69099000 |
| Wednesday, January 1, 2020 | 59392000 | 75961000 |
| Friday, January 1, 2021 | 69012000 | 90467000 |
| Saturday, January 1, 2022 | 36082000 | 74552000 |
| Sunday, January 1, 2023 | 24537000 | 91593000 |
Unlocking the unknown
In the competitive world of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Ligand Pharmaceuticals Incorporated and Supernus Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D allocations.
From 2014 to 2023, Supernus Pharmaceuticals consistently outpaced Ligand in R&D spending, with a peak in 2023 where their investment reached approximately 91.6 million, nearly 30% higher than Ligand's 24.5 million. This trend highlights Supernus's aggressive approach to innovation, particularly evident in 2018 when their R&D expenses surged by over 80% compared to the previous year.
Conversely, Ligand's R&D spending peaked in 2021, reflecting a more conservative yet steady growth strategy. These insights underscore the diverse approaches within the pharmaceutical industry, where strategic R&D investments can significantly influence a company's market position and future growth.
Eli Lilly and Company or Ligand Pharmaceuticals Incorporated: Who Invests More in Innovation?
Comparing Innovation Spending: Amgen Inc. and Ligand Pharmaceuticals Incorporated
R&D Insights: How Zoetis Inc. and Supernus Pharmaceuticals, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Insmed Incorporated and Supernus Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ligand Pharmaceuticals Incorporated
Research and Development Investment: Ionis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Alkermes plc vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Alpine Immune Sciences, Inc. and Supernus Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
R&D Spending Showdown: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Analyzing R&D Budgets: Vericel Corporation vs Supernus Pharmaceuticals, Inc.
Comparing Innovation Spending: Ligand Pharmaceuticals Incorporated and Evotec SE